Udvalget besluttede, at fordelene ved Revatio er større end risiciene til behandling af PAH klassificeret som WHO funktionel- klasse III for at forbedre den fysiske kapacitet.
The Committee decided that Revatio’ s benefits are greater than its risks for the treatment of PAH classified as WHO functional class III, to improve exercise capacity.